The urokinase receptor

Fibrinolysis and Proteolysis

Volumn 12, Issue 4, 1998, Pages 191-204

  Behrendt, N ^a   Stephens, R W ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR;

EXTRACELLULAR MATRIX; LIGAND BINDING; MACROPHAGE ACTIVATION; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR GENE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0031767901     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80013-1     Document Type: Review

References (152)

1. r 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92.
2. Stoppelli M P, Corti A, Soffientini A, Cassani G, Blasi F, Assoian R K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939-4943.
3. Bajpai A, Baker J B. Cryptic urokinase binding sites on human foreskin fibroblasts. Biochem Biophys Res Commun 1985; 133: 475-482.
4. Danø K, Andreasen P A, Grøndahl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
5. Andreasen P A, Kjøller L, Christensen L, Duffy M J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
6. Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988; 2: 73-84.
7. Pöllänen J, Hedman K, Nielsen L S, Danoø K, Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988; 106: 87-95.
8. Ellis V, Scully M F, Kakkar V V, Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 2185-2188.
9. Stephens R W, Pöllänen J, Tapiovaara H, et al. Activation of prourokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-1995.
10. Wang Y, Dang J, Johnson L K, Selhamer JJ, Doe W F. Structure of the human urokinase receptor gene and its similarity to CD59 and the Ly-6 family. Eur J Biochem 1995; 227: 116-122.
11. Børglum A D, Byskov A, Ragno P, et al. Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. Am J Hum Genet 1992; 50: 492-497.
12. Min H Y, Semnani R, Mizukami I F, Watt K, Todd R F, Liu D Y. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J Immunol 1992; 148: 3636-3642.
13. Todd R F, Barnathan E S, Bohuslav J, et al. CD87 cluster workshop report. In: Schlossman S F, Boumsell L, Gilks W, et al (eds). Leukocyte Typing V. White Cell Differentiation Antigens. Oxford: Oxford University Press, 1995; 932-939.
14. Sitrin R G, Todd R F, Mizukami I F, Gross T J, Shollenberger S B, Gyetko M R. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood 1994; 84: 1268-1275.
15. Almus Jacobs F, Varki N, Sawdey M S, Loskutoff D J. Endotoxin stimulates expression of the murine urokinase receptor gene in vivo. Am J Pathol 1995; 147: 688-698.
16. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8: 189-203.
17. Picone R, Kajtaniak E L, Nielsen L S, et al. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 1989; 108: 693-702.
18. Cubellis M V, Nolli M L, Cassani G, Blasi F. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 1986; 261: 15819-15822.
19. r receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 1988; 263: 2358-2363.
20. Haddock R C, Spell M L, Baker C D, et al. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem 1991; 266: 21466-21473.
21. Behrendt N, Rønne E, Danø K. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 1996; 271: 22885-22894.
22. Wei Y, Waltz D A, Rao N, Drummond RJ, Rosenberg S, Chapman H A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
23. 2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990; 265: 6453-6460.
24. Solberg H, Løber D, Eriksen J, et al. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. Eur J Biochem 1992; 205: 451-458.
25. Roldan A L, Cubellis M V, Masucci M T, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-474.
26. Kristensen P, Eriksen J, Blasi F, Danø K. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 1991; 115: 1763-1771.
27. Rabbani S A, Rajwans N, Achbarou A, Murthy K K, Goltzman D. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. FEBS Lett 1994; 338: 69-74.
28. De Young M B, Wohlgemuth, J, Newman K D, Dichek D A. Modulation of vascular cell plasminogen activation by gene transfer in vitro. Fibrinolysis & Proteolysis 1997; 11 (Suppl. 3): abstract 186.
29. Reuning U, Little S P, Dixon E P, Johnstone E M, Bang N U. Molecular cloning of cDNA for the bovine urokinase-type plasminogen activator receptor. Thromb Res 1993; 72: 59-70.
30. Krätzschmar J, Haendler B, Kojima S, Rifkin D B, Schleuning WD. Bovine urokinase-type plasminogen activator and its receptor: cloning and induction by retinoic acid. Gene 1993; 125: 177-183.
31. Ploug M, Rønne E, Behrendt N, Jensen A L, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266: 1926-1933.
32. Møller L B, Ploug M, Blasi F. Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator. Eur J Biochem 1992; 208: 493-500.
33. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Danø K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 1991; 266: 7842-7847.
34. Palfree R G. The urokinase-type plasminogen activator receptor is a member of the Ly-6 superfamily [letter]. Immunol Today 1991; 12: 170.
35. Ploug M, Rahbek Nielsen H, Ellis V, Roepstorff P, Danø K. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochemistry 1995; 34: 12524-12534.
36. Albrecht J C, Nicholas J, Cameron J R, Newman C, Fleckenstein B, Honess R W. Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. Virology 1992; 190: 527-530.
37. Gumley T P, McKenzie I F, Kozak C A, Sandrin M S. Isolation and characterization of cDNA clones for the mouse thymocyte B cell antigen (ThB). J Immunol 1992; 149: 2615-2618.
38. Brakenhoff R H, Gerretsen M, Knippels E M, et al. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J Cell Biol 1995; 129: 1677-1689.
39. 2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J Biol Chem 1993; 268: 17539-17546.
40. Sugita Y, Nakano Y, Oda E, Noda K, Miura N H, Tomita M. Determination of carboxyl-terminal residue and disulfide bonds of MACIF (CD59), a glycosyl-phosphatidylinositol-anchored membrane protein. J Biochem Tokyo 1993; 114: 473-477.
41. Kieffer B, Driscoll P C, Campbell I D, Willis A C, van der Merwe P A, Davis S J. Three-dimensional structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins. Biochemistry 1994; 33: 4471-4482.
42. Flectcher C M, Harrison R A, Lachmann P J, Neuhaus D. Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure 1994; 2: 185-199.
43. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett 1994; 349: 163-168.
44. Ploug M, Rahbek-Nielsen H, Nielsen P F, Roepstorff P, Danø K. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells. J Biol Chem 1998; 273: 13933-13943.
45. Rønne E, Behrendt N, Ploug M, et al. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J Immunol Methods 1994; 167: 91-101.
46. Ploug M, Ellis V, Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1994; 33: 8991-8997
47. Appella E, Robinson E A, Ullrich SJ, et al. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987; 262: 4437-4440.
48. 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 1994; 33: 15418-15424.
49. Hansen A P, Petros A M, Meadows R P, et al. Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 1994; 33: 4847-4864.
50. Magdolen V, Rettenberger P, Koppitz M, et al. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur J Biochem 1996; 237: 743-751.
51. Møller L B, Pöllänen J, Rønne E, Pedersen N, Blasi F. N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand. J Biol Chem 1993; 268: 11152-11159.
52. Ploug M, Østergaard S, Hansen L B L, Holm A, Danø K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 1998; 37: 3612-3622.
53. Høyer-Hansen G, Rønne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267: 18224-18229.
54. Solberg H, Rømer J, Brünner N, et al. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 1994; 58: 877-881.
55. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997; 243: 21-26.
56. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15: 1572-1582.
57. Pedersen N, Schmitt M, Rønne E, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993; 92: 2160-2167
58. Lau H K, Kim M. Soluble urokinase receptor from fibrosarcoma HT-1080 cells. Blood Coagul Fibrinolysis 1994; 5: 473-478.
59. Rønne E, Pappot H, Grøndahl-Hansen J, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 89: 576-581.
60. Nowak U K, Li X, Teuten A J, Smith R A, Dobson C M. NMR studies of the dynamics of the multidomain protein urokinase-type plasminogen activator. Biochemistry 1993; 32: 298-309.
61. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-12758.
62. Behrendt N, Danø K. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. FEBS Lett 1996; 393: 31-36.
63. Ellis V. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. J Biol Chem 1996; 271: 14779-14784.
64. Petersen L C, Lund L R, Nielsen L S, Danø K, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988; 263: 11189-11195.
65. Petersen L C. Kinetics of reciprocal pro-urokinase/plasminogen activation - stimulation by a template formed by the urokinase receptor bound to poly(D-lysine). Eur J Biochem 1997; 245: 316-323.
66. 2-terminal domain of the urokinase receptor. FEBS Lett 1991; 288: 233-236.
67. Behrendt N, Rønne E, Danø K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler 1995; 376: 269-279.
68. Higazi A, Cohen R L, Henkin J, Kniss D, Schwartz B S, Cines D B. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem 1995; 270: 17375-17380.
69. Higazi A A. Commentary on: 'Effect of purified soluble urokinase receptor on the plasminogen prourokinase activation system' by N. Behrendt and K. Danø. FEBS Lett 1996; 393: 31-36. FEBS Lett 1997; 402: 291-292.
70. Behrendt N, Danø K. Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' FEBS Lett 1997; 402: 293-294.
71. Wang J, Mazar A, Quan N, Schneider A, Henkin J. Plasminogen activation by pro-urokinase in complex with its receptor-dependence on a tripeptide (Spectrozyme plasmin). Eur J Biochem 1997; 247: 256-261.
72. Stephens R W, Tapiovaara H, Reisberg T, Bizik J, Vaheri A. Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Cell Regul 1991; 2: 1057-1065.
73. Pöllänen J, Vaheri A, Tapiovaara H, et al. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Proc Natl Acad Sci USA 1990; 87: 2230-2234.
74. Ellis V, Wun T C, Behrendt N, Rønne E, Danø K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 1990; 265: 9904-9908.
75. Kanse S M, Kost C, Wilhelm O G, Andreasen P A, Preissner K T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224: 344-353.
76. Høyer-Hansen G, Behrendt N, Ploug M, Danø K, Preissner K T. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 1997; 420: 79-85.
77. Deng G, Curriden S A, Wang S, Rosenberg S, Loskutoff D J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? Cell Biol 1996; 134: 1563-1571.
78. Waltz D A, Natkin L R, Fujita R M, Wei Y, Chapman H A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100: 58-67.
79. Seiffert D, Loskutoff D J. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 1991; 266: 2824-2830.
80. Deng G, Royle G, Wang S, Crain K, Loskutoff D J. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 1996; 271: 12716-12723.
81. Cubellis M V, Wun T C, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBOJ 1990; 9: 1079-1085.
82. Estreicher A, Muhlhauser J, Carpentier J L, Orci L, Vassalli J D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111: 783-792.
83. Herz J, Clouthier D E, Hammer R E. LDL receptor-related protein internalizes and degrades u-PA-PAI-1 complexes and is essential for embryo implantation Cell 1992; 71: 411-421 [published erratum appears in Cell 1993; 73(3): 428].
84. Nykjaer A, Petersen C M, Møller B, et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase. Plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992; 267: 14543-14546.
85. Kounnas M Z, Henkin J, Argraves W S, Strickland D K. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of prourokinase. J Biol Chem 1993; 268: 21862-21867.
86. Moestrup S K, Nielsen S, Andreasen P, et al. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J Biol Chem 1993; 268: 16564-16570.
87. Heegaard C W, Simonsen A C, Oka K, et al. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem 1995; 270: 20855-20861.
88. Nykjaer A, Conese M, Christensen E I, et al. Recycling of the urokinase receptor upon internalization of the u-PA:serpin complexes. EMBO J 1997; 16: 2610-2620.
89. Xue W, Kindzelskii A L, Todd R F, Petty H R. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 1994; 152: 4630-4640.
90. Bohuslav J, Horejsi V, Hansmann C, et al. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 1995; 181: 1381-1390.
91. Sitrin R G, Todd R F, Petty H R, Brock T G, Shollenberger S B. Albrecht E, Gyetko M R, The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996; 97: 1942-1951.
92. Kindzelskii A L, Laska Z O, Todd R F, Petty H R. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2′ CD11b/CD18) during neutrophil polarization. J Immunol 1996; 156: 297-309.
93. Todd R F, Petty H R. Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. J Lab Clin Med 1997; 129: 492-498.
94. Wei Y, Lukashev M, Simon D I, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
95. Xue W, Mizukami I, Todd R F, Petty H R. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 1997; 57: 1682-1689.
96. Simon D I, Rao N K, Xu H, et al. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996; 88: 3185-3194.
97. Hebert C A, Baker J B. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol 1988; 106: 1241-1247.
98. Low M G. The glycosyl-phosphatidylinositol anchor of membrane proteins. Biochim Biophys Acta 1989; 988: 427-454.
99. Sargiacomo M, Sudol M, Tang Z, Lisanti M P. Signal
100. transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 1993; 122: 789-807.
101. Stahl A, Mueller B M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 1995; 129: 335-344.
102. Schnitzer J E, McIntosh D P, Dvorak A M, Liu J, Oh P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science 1995; 269: 1435-1439.
103. Behrendt N, Rønne E, Danø K. A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking. FEBS Lett 1993; 336: 394-396.
104. Bugge T H, Suh T T, Flick M J, et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 1995; 270: 16886-16894.
105. Dewerchin M, Nuffelen A V, Wallays G, et al. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 1996; 97: 870-878.
106. Bugge T H, Flick M J, Danton M J, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899-5904.
107. Herbert J M, Carmeliet P. Involvement of u-PA in the antiapoptotic activity of TGFbeta for vascular smooth muscle cells. FEBS Lett 1997; 413: 401-404.
108. Kristensen P, Eriksen J, Danø K. Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. J Histochem Cytochem 1991; 39: 341-349.
109. Carmeliet P, Collen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Semin Thromb Hemost 1996; 22: 525-542.
110. Behrendt N, Rønne E, Danø K. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J Biol Chem 1993; 268: 5985-5989.
111. La Rocca R V, Stein C A, Myers C E. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells 1990; 2: 106-115.
112. Goodson RJ, Doyle M V, Kaufman S E, Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA 1994; 91: 7129-7133.
113. Ballance D J, Marshall J M, Cottingham I R, et al. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor. Eur J Biochem 1992; 207: 177-183.
114. Kobayashi H, Gotoh J, Hirashima Y, Fujie M, Sugino D, Terao T, Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem 1995; 270: 8361-8366.
115. Cavallaro U, del Vecchio A, Lappi D A, Soria M R. A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J Biol Chem 1993; 268: 23186-23190.
116. Bagshawe K. Antibody-directed enzyme prodrug therapy: a review. Drug Develop Res 1995; 34: 220-230.
117. Wolf H, Freimann U, Jung G. Target cell induced T cell activation with bispecific antibodies: a new concept for tumor immunotherapy. Rec Results Cancer Res 1994; 135: 185-195.
118. Bron R, Ortiz A, Wilschut J. Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes). Biochemistry 1994; 33: 9110-9117.
119. Wagner E, Curiel D, Gotten M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv Drug Deliv Rev 1994; 14: 113-135.
120. Crowley C W, Cohen R L, Lucas B K, Liu G, Shuman M A, Levinson A D. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5025.
121. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N, Terao T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 1994; 57: 727-733.
122. Kook Y H, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 13: 3983-3991.
123. Min H Y, Doyle L V, Vitt C R, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-2433.
124. Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997; 137: 767-777.
125. Needham G K, Sherbet G V, Farndon J R, Harris A L. Binding of urokinase to specific receptor sites on human breast cancer membranes. Br J Cancer 1987; 55: 13-16.
126. Pyke C, Graem N, Ralfkiaer E, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993; 53: 1911-1915.
127. Bianchi E, Cohen R L, Thor A T, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 861-866.
128. Pyke C, Kristensen P, Ralfkiaer E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059-1067
129. Ganesh S, Sier C F, Heerding M M, Griffioen G, Lamers C B, Verspaget H W. Urokinase receptor and colorectal cancer survival [letter]. Lancet 1994; 344: 401-402.
130. Pedersen H, Brünner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-4675.
131. Grondahl-Hansen J, Peters H A, van Putten W L J, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079-1087.
132. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly J J, Duffy M J. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995; 61: 597-600.
133. Rønne E, Høyer-Hansen G, Brünner N, et al. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 1995; 33: 199-207
134. Ploug M, Eriksen J, Plesner T, Hansen N E, Danø K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem 1992; 208: 397-404.
135. Stephens R W, Pedersen A N, Nielsen H J, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997; 43: 1868-1876.
136. Pappot H, Høyer-Hansen G, Rønne E, et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997; 33: 867-872.
137. Heiss M M, Allgayer H, Gruetzner K U, et al. Individual development and u-PA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med 1995; 1: 1035-1039.
138. Sier C F M, Stephens R, Bizik J, et al. The level of urokinase plasminogen activator receptor (uPAR) is increased in serum of ovarian cancer patients. Cancer Res 1998; 58: 1843-1849.
139. Blasi F, Stoppelli M P, Cubellis M V. The receptor for urokinase-plasminogen activator. J Cell Biochem 1986; 32: 179-186.
140. Bürgle M, Koppitz M, Riemer C, et al. Inhibition of the interaction of urokinase-type plasminogen activator (u-PA) with its receptor (uPAR) by synthetic peptides. Biol Chem 1997; 378: 231-237.
141. Kirchheimer J C, Wojta J, Christ G, Binder B R. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 1989; 86: 5424-5428.
142. Mohanam S, Sawaya R, McCutcheon I, Ali Osman F, Boyd D, Rao J S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 1993; 53: 4143-4147
143. Luther T, Magdolen V, Albrecht S, et al. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997; 150: 1231-1244.
144. Ellis V, Danø K. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochem J 1993; 296: 505-510.
145. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (u-PA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 1994; 337: 131-134.
146. Kariko K, Megyeri K, Xiao Q, Barnathan E S. Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett 1994; 352: 41-44.
147. Quattrone A, Fibbi G, Anichini E, et al. Antimessenger oligonucleotide for urokinase receptor gene inhibits invasivity of transformed human fibroblasts. Anticancer Drug Des 1995; 10: 97-102.
148. Ossowski L. Effect of antisense inhibition of Urokinase receptor on malignancy. Curr Top Microbiol Immunol 1996; 213: 101-112.
149. Go Y, Chintala S K, Mohanam S, et al. Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin Exp Metastasis 1997; 15: 440-446.
150. Lu H, Yeh P, Guitton J D, et al. Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett 1994; 356: 56-59.
151. Lu H, Mabilat C, Yeh P, et al. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett 1996; 380: 21-24.
152. Kost T A, Ignar D M, Clay W C, et al. Production of a urokinase plasminogen activator-IgG fusion protein (u-PA-IgG) in the baculovirus expression system. Gene 1997; 190: 139-144.